Oral S-1 in advanced cutaneous squamous cell carcinoma
Oral S-1 in advanced cutaneous squamous cell carcinoma
复制标题
DOI：
10.1111/1346-8138.12498
复制
发表时间：
2014-06-01
影响因子：
3.1
通讯作者：
Yamamoto, Akifumi
中科院分区：
文献类型：
--
作者：
Teramoto, Yukiko;Nakamura, Yasuhiro;Yamamoto, Akifumi
鳞状细胞癌（SCC）是日本第二常见的皮肤癌，近年来发病率一直在上升。早期诊断和完全切除可提供高治愈率。然而，晚期鳞状细胞癌表现为局部浸润、区域淋巴结转移或远处转移，无法治愈，难以单独手术治疗。一些化疗方案已用于治疗晚期皮肤SCC。然而，几乎所有这些方案都需要静脉内给药，并在老年人中导致严重的毒性。我们给了S-1，一种新的口服化疗药物，用于6例晚期皮肤SCC患者。3例患者获得完全缓解，1例获得部分缓解。2例患者病情稳定。总有效率为66.7%（6例患者中有4例），疾病控制率为100%。6名患者中有2名出现3级贫血。口服S-1治疗晚期皮肤SCC安全有效。然而，有必要进行前瞻性试验来证实口服S-1治疗晚期皮肤SCC的有效性。
Squamous cell carcinoma (SCC) is the second most common type of skin cancer in Japan, and its incidence has been increasing in recent years. Early diagnosis and complete excision can provide a high cure rate. However, advanced cases of SCC showing local invasion, regional lymph node metastasis or distant metastasis are not curative and are difficult to treat with surgery alone. Some chemotherapy regimens have been used for treating advanced cutaneous SCC. However, almost all these regimens require intravenous administration and result in serious toxicities in elderly people. We gave S-1, a novel oral chemotherapeutic agent, for six patients with advanced cutaneous SCC. Three patients achieved complete response and one achieved partial response. Two patients showed stable disease. The overall response rate was 66.7% (four of six patients), and the disease control rate was 100%. Two of six patients developed grade 3 anaemia. Oral S-1 treatment is safe and effective for treating advanced cutaneous SCC. However, a prospective trial is necessary to confirm the effectiveness of oral S-1 for advanced cutaneous SCC.